Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 7/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.35 |
| ▸ | CTPS1 | P17812 | 6/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416047 | 1.00 | APLNR (0.36) | APLNRCXCR3CTPS1TAS2R14PTGES | |
| SCHEMBL21392057 | 0.87 | APLNR (0.38) | APLNRCXCR3TAS2R14PTGES | |
| SCHEMBL30416333 | 0.87 | APLNR (0.38) | APLNRCXCR3TAS2R14PTGES | |
| Potassium Ion SCHEMBL25285698 | 0.85 | TAS2R14 (0.36) | APLNRCXCR3TAS2R14PTGES | |
| SCHEMBL22924965 | 0.82 | APLNR (0.38) | APLNRCXCR3TAS2R14PTGES | |
| SCHEMBL22924968 | 0.81 | APLNR (0.35) | APLNRTAS2R14PTGES | |
| Potassium SCHEMBL30882859 | 0.81 | APLNR (0.38) | APLNRCXCR3TAS2R14PTGES | |
| SCHEMBL29228057 | 0.81 | APLNR (0.38) | APLNRCXCR3TAS2R14PTGES | |
| SCHEMBL21392246 | 0.81 | APLNR (0.35) | APLNRCXCR3 | |
| Potassium Ion SCHEMBL30725705 | 0.81 | APLNR (0.37) | APLNRCXCR3TAS2R14PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111868051-B | Aminopyrimidine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-112839938-B | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20210387965-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2021-12-16 | — | — | US | disclosed |
| CN-112839938-A | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2021-05-25 | — | — | CN | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| CN-111868051-A | Aminopyrimidine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019180244-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019179652-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024507-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | APLNR 3512/4885CXCR3 1155/4885CTPS1 2586/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | APLNR 3512/4885CXCR3 1155/4885CTPS1 2586/4885 |
| US-20210387965-A1 | Compounds | CYP1A1, UGT1A1, CYP1B1 | APLNR 3505/4885CXCR3 1113/4885CTPS1 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.